In pancreatic cancer, loss of RUNX3 expression leads to the upregulation of multidrug resistance proteins (MRP), consequently increasing resistance to gemcitabine and adversely affecting patient prognosis [88]. Here, RUNX3 is linked to pancreatic neoplasm.